Navigation Links
REiNS collaboration seeks common outcome measures for neurofibromatosis clinical trials
Date:12/9/2013

Philadelphia, Pa. (December 9, 2013) - As potentially effective new treatments for neurofibromatosis (NF) are developed, standardized research approachesincluding outcome measures specific to NFare needed. The first report from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration has been published as a supplement to Neurology, the Official Journal of the American Academy of Neurology (AAN). The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

The (REiNS) Collaboration was formed to achieve consensus regarding the design of clinical trials for treatments of NF and related disorders, with a focus on developing a standard set of appropriate and meaningful outcome measures. "This supplement presents the initial progress of several of the working groups and includes the first series of consensus recommendations for NF clinical trial endpoints by the REiNS International Collaboration," according to an introduction by Dr Scott R. Plotkin and colleagues. The full supplement is freely available on the journal website.

Initial Reports on Consensus Approach to NF Clinical Trials

The REiNS Collaboration was established at the 2011 meeting of the Children's Tumor Foundation. The neurofibromatosesNF1, NF2, and schwannomatosisare a group of related genetic diseases in which patients are predisposed to developing multiple tumor types, particularly tumors of the nerve sheath. Other manifestations may occur as well, including learning problems in patients with NF1 and cataracts in those with NF2. Especially for NF1, the disease is usually diagnosed in childhood.

Traditionally, surgery has been the standard treatment for NF tumors. But recent advances in scientific understanding of the biology and development of NF have raised the promise of new targeted antitumor agents. An ambitious research agenda has been developed for rapid evaluation of these emerging NF treatments.

Most early NF studies used designs similar to those for cancer treatments. But these research designsoften focusing on tumor size or overall survivalmay not be relevant to NF. Neurofibromatosis tumors are typically benign, rather than malignant, and patients face unique clinical and functional problems. "The NF community continues to struggle with the optimum design of clinical trials for this group of patients," Dr Plotkin and coauthors write.

A major goal of the REiNS Collaboration is to develop standardized outcome measures for use in NF clinical trials. The collaborators are organized into seven working groups, focusing on imaging of tumor response, functional outcomes, visual outcomes, patient-reported outcomes, neurocognitive outcomes, and whole-body magnetic resonance imaging (MRI), and disease biomarkers. The new supplement includes initial working group reports addressing:

  • Patient-reported outcomes, especially pain.
  • Functional outcomes affecting visionimportant because of the high rate of tumors affecting the optic nerve in NF1.
  • Hearing and facial function outcomes, addressing the high rate of hearing loss and facial weakness in NF2.
  • Imaging tumor responseMRI with volumetric analysis is recommended to show changes in tumor size.

By developing consensus outcome measures relevant to NF, the REiNS collaborators hope to promote rapid evaluation of treatments that may benefit individuals affected by these disorders. "Ultimately, we plan to engage industry partners and national regulatory agencies in this process to facilitate approval of drugs for patients with NF," Dr Plotkin and coauthors write.

They add that the recommendations will likely be modified over time, as more data on NF-specific endpoints become available. Future modifications to the recommendations and other updates will be shared with the NF research community through the REiNS website: http://www.reinscollaboration.org.


'/>"/>

Contact: Connie Hughes
Connie.Hughes@wolterskluwer.com
646-674-6348
Wolters Kluwer Health
Source:Eurekalert

Related medicine news :

1. UT MD Anderson scientists find protein that reins in runaway network
2. Darvone-Darvocet Failure to Warn Claims Reinstated against Generic Drug Maker Wright & Schulte LLC Report
3. Global Reinsurance Carriers Industry Market Research Report from IBISWorld Has Been Updated
4. Barbara Lopez Kunz Takes the Reins as DIA’s Global Chief Executive
5. Mayo Clinic, Dartmouth-Hitchcock announce collaboration
6. Treating the whole person with autism sets direction for parent-clinician collaboration
7. Astex, CRT and the Institute of Cancer Research announce epigenetic drug discovery collaboration
8. New collaboration to develop treatments for liver disease
9. Mass. Eye and Ear, Joslin Diabetes announce collaboration in eye care
10. Merck and Regenstrief Institute establish evidence-based care collaboration
11. Kentucky receives top honors in nations capital for health IT collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... Philadelphia, PA (PRWEB) , ... June 28, 2017 ... ... will host a one-day corporate governance program for mid-market executives as a kick-off ... will be held Sunday, Sept. 24, 2017 on the University of Pennsylvania campus, ...
(Date:6/28/2017)... Vancouver, British Columbia (PRWEB) , ... June 28, ... ... (OTCQB: CNZCF) (FSE: ZEON) is pleased to announce that a two year study ... using the Company's Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. ...
(Date:6/28/2017)... ... June 28, 2017 , ... Designers ... to communities in northern Virginia and DC, is announcing a cooperative charity event ... with Alzheimer’s and other disorders that lead to memory impairment. , The Insight ...
(Date:6/27/2017)... Rolling Meadows, IL (PRWEB) , ... June 27, ... ... they are considering a cosmetic treatment, according to survey data released today by ... Consumer Survey on Cosmetic Dermatologic Procedures indicates the percentage of consumers considering ...
(Date:6/27/2017)... ... 2017 , ... Salucro, the cloud-based payment platform that has ... and provider groups, has announced that it will now offer Parasail’s payment plans ... San Francisco health-finance startup that has launched a series of tech-based products that ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... , June 14, 2017 The Bio Supply ... City of Fremont and the Biomedical ... bio-pharma industry in California by ... executive networking, and fostering workforce development. The primary focus ... growth of start-ups, as well as small and mid-sized ...
(Date:6/11/2017)... 2017  Eli Lilly and Company (NYSE: LLY ... studies of galcanezumab, an investigational treatment for the prevention ... several key secondary endpoints for galcanezumab compared to placebo ... (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented today at ... Boston . "The ...
(Date:6/8/2017)... , June 8, 2017  Less than a ... hit more than 200,000 companies, including hospital networks, in ... heralded as one of the largest online extortion attempts ... the healthcare market, it is imperative that providers understand ... their data from this — and many other very ...
Breaking Medicine Technology: